Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

ock-based compensation expense
  • Net loss of $8 million to $10 million
  • Basic and diluted net loss of $0.20 to $0.25 per share
  • Year-end cash, cash equivalents and investments available for sale balance greater than $30 million
  • Revenues:"We expect development revenues in 2013 will be comprised of approximately $19 million in committed R&D funding and license fee revenues from existing collaborations, and we anticipate $6 million to $9 million in additional license fees, R&D funding, milestones and cost reimbursements," Rogers noted. 

    "We forecast the vast majority of 2013 commercial revenues to be based on existing collaboration agreements.  While it remains difficult to forecast commercial revenues due to uncertainties around product launch timing, the number of product lines that will include our flavor ingredients, and other factors, we are currently estimating 2013 commercial revenues to be approximately $6 million.

    "2013 should prove to be a transitional year for Senomyx as we implement our direct sales strategy," Rogers stated.  "While direct sales are not expected to yield significant results in 2013, our goal is for direct sales to be a key driver of meaningful commercial revenues in future years.

    Expenditures:"Looking at expenditures, as we consider our resource requirements over the next several years for R&D, G&A and Commercial Operations, excluding the cost of commercial revenues, we expect we will be able to manage our expenses to be generally in-line with our 2013 expense guidance range, subject to quarterly fluctuations and increases for inflation.
    With respect to the expanded commercial organization activities in support of our direct sales strategy, many of the functions will be handled by existing Senomyx personnel.  In other cases, such as supply chain and account management, we will add dedicated resources to support these functions.
    '/>"/>

    SOURCE Senomyx
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    7. WuXi PharmaTech Announces Third-Quarter 2011 Results
    8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    9. Spherix Announces Third Quarter Financial Results
    10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a commercial focus on ... and Drug Administration (CFDA) has approved the Company,s application ... ovarian clear cell carcinoma (OCCC) patients for its proprietary ...
    (Date:3/30/2015)... , March 30, 2015    Intrexon ... in synthetic biology, and Merck Serono, the biopharmaceutical ... , today announced an exclusive strategic collaboration ... Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration ... innovative therapies that modulate the immune system,s natural ...
    (Date:3/30/2015)... (PRWEB) March 29, 2015 A two-day ... United States and plenary talks by four leading photonics ... Optics + Optoelectronics next month in Prague, Czech ... in 17 conferences alongside a two-day exhibition. Sponsored by ... , the event will run 13-16 April in the ...
    (Date:3/30/2015)... PARK, N.J. , March 30, 2015 /PRNewswire/ ... (PAMORA) under development by Shionogi & Co., Ltd., ... phase III study (COMPOSE I) for the treatment ... chronic non-cancer pain receiving opioid therapy. Study results ... daily) statistically significantly improved the frequency of spontaneous ...
    Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
    ... Cellectricon appoints David Burns as the company,s ... highly impressive international Life Science executive track record ... expansion in bringing state-of-the-art screening solutions for drug ... has extensive experience of the life sciences industry ...
    ... SomaGenics, Inc., a biotechnology company specializing in RNA-based ... interference (RNAi) therapeutics against Hepatitis C virus (HCV) based ... along with its collaborators at Tekmira Pharmaceuticals and Roche, ... shRNAs are Potent Inhibitors of Hepatitis C Virus in ...
    ... SAN DIEGO, Sept. 20, 2011 BioSurplus announced today ... a senior service engineer.  With over 25 years of ... rapidly-growing services division, which includes preventive and corrective work ... (Photo: http://photos.prnewswire.com/prnh/20110920/LA71370 ) While at Thermo ...
    Cached Biology Technology:David Burns Appointed CEO/President of Cellectricon 2SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus 2SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus 3BioSurplus Hires Top Service Engineer, Roswell Pund 2
    (Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
    (Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
    (Date:3/20/2015)... DUBLIN , Mar. 19, 2015 Research and Markets ... the "Hand Geometry - Global Strategic Business Report" ... worldwide markets for Hand Geometry in US$ Thousands. The report ... , Japan , Europe ... America , and Rest of World. Annual ...
    Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
    ... 2012 Listed below are the selected highlights for the ... Genetics . The July issue is available online ... Vol. 191, JULY 2012, Copyright 2012. ISSUE ... in mouse genetic studies through the use of meta-analysis for ...
    ... being enlisted in the fight to save dugongs from the ... thanks to the creative mind of marine biologist Dr Mariana ... Symposium, in Cairns her new book takes readers into ... the Torres Strait. , In ,Dhyum the dugong, the author, ...
    ... "Paper of the Week" by Wai Mun Huang and ... the University of Minnesota reveals new insights into the molecular ... the pathogen responsible for crown gall disease, a tumor-forming infection ... The bacterium is parasitic: It infects its plant ...
    Cached Biology News:Genetics Society of America's Genetics journal highlights for July 2012 2Genetics Society of America's Genetics journal highlights for July 2012 3New book inspires children to protect dugongs 2New book inspires children to protect dugongs 3
    ... Fernbach-style culture flasks have triple baffles located ... to achieve maximal oxygen transfer to culture ... Delong-style 38mm neck for use with plastic ... see Nos. CLS2679638 or CLS2679738. These flasks ...
    ... template is designed to allow neomycin/kanamycin ... The FRT-PGK-gb2-neo-FRT template encodes the neomycin/kanamycin resistance ... for expression of kanamycin resistance in ... for expression of neomycin resistance in mammalian ...
    ... inch long PYREX NMR tubes are made from ... valves, and vacuum racks. They are designed for ... 500MHz. They have an O.D. of 4.97 + ... These NMR tubes can be used with the ...
    Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
    Biology Products: